ストックスクリーナーアプリを入手
70.23
1.61%
-1.15
アフターアワーズ：
70.23
前日終値:
$71.38
開ける：
$70.62
24時間の取引高:
953.29K
Relative Volume:
0.62
時価総額：
$7.72B
収益：
$628.56M
当期純損益:
$141.82M
株価収益率:
55.74
EPS:
1.26
ネットキャッシュフロー:
$142.60M
1週間 パフォーマンス:
-3.49%
1か月 パフォーマンス:
-3.75%
6か月 パフォーマンス:
+17.84%
1年 パフォーマンス:
+164.02%
1日の値動き範囲:
$69.74
$71.27
1週間の範囲:
$67.00
$75.41
52週間の値動き範囲:
$26.53
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
名前
Corcept Therapeutics Inc
セクター
電話
650.688.8803
住所
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
70.23 | 7.72B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-06 | アップグレード | Truist | Hold → Buy |
| 2023-04-11 | 開始されました | SVB Securities | Market Perform |
| 2023-04-04 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-01 | ダウングレード | Truist | Buy → Hold |
| 2022-07-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-06-27 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-02 | 開始されました | Canaccord Genuity | Buy |
| 2022-01-28 | 開始されました | Truist | Buy |
| 2020-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-09-24 | 開始されました | Jefferies | Buy |
| 2019-09-06 | 開始されました | H.C. Wainwright | Buy |
| 2019-02-04 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 繰り返されました | Stifel | Hold |
| 2018-05-31 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-09 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 開始されました | Stifel | Buy |
| 2017-02-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-04-21 | 開始されました | FBR Capital | Outperform |
| 2014-01-13 | ダウングレード | Stifel | Buy → Hold |
| 2013-08-09 | ダウングレード | Janney | Buy → Neutral |
| 2013-08-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-01-06 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | アップグレード | Punk, Ziegel & Co | Mkt Perform → Accumulate |
すべてを表示
Corcept Therapeutics Inc (CORT) 最新ニュース
Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call - ACCESS Newswire
Corcept Therapeutics chief development officer sells $524,652 in stock - Investing.com Australia
Insider Sell: William Guyer Sells Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2025 Earnings Call Transcript - Insider Monkey
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall - MSN
Corcept Therapeutics price target lowered to $135 from $150 at Truist - Yahoo Finance
Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS - Yahoo Finance
Corcept Therapeutics (CORT) Faces Price Target Cut Amid Revenue Concerns | CORT Stock News - GuruFocus
Assessing Corcept Therapeutics: Insights From 9 Financial Analysts - Benzinga
Truist Cuts Price Target on Corcept Therapeutics to $135 From $150, Keeps Buy Rating - marketscreener.com
H.C. Wainwright cuts Corcept Therapeutics target to $145 By Investing.com - Investing.com Nigeria
Corcept Therapeutics (CORT) Receives Revised Price Target from A - GuruFocus
Corcept Therapeutics (CORT) Maintains Buy Rating Amid Revised Price Target | CORT Stock News - GuruFocus
Corcept Therapeutics Inc Q1 2025 Earnings: EPS of $0.17 Beats Es - GuruFocus
Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges - GuruFocus
Decoding Corcept Therapeutics Inc (CORT): A Strategic SWOT Insig - GuruFocus
Corcept Therapeutics Reports Q1 2025 Financial Results - TipRanks
Corcept Therapeutics Stock Jumps On Record Prescription Volume: Retail Sentiment Soars - MSN
Corcept: Q1 Earnings Snapshot - MySA
Corcept Therapeutics (CORT) Anticipates Future Growth Amid Reven - GuruFocus
Corcept Therapeutics (CORT) Set to Announce Q1 Earnings - GuruFocus
Earnings call transcript: Corcept Therapeutics Q1 2025 earnings beat expectations By Investing.com - Investing.com UK
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates - Yahoo Finance
Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops - Yahoo Finance
Corcept Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CORCEPT THERAPEUTICS Earnings Results: $CORT Reports Quarterly Earnings - Nasdaq
Corcept Therapeutics Q1 Earnings Decrease, Revenue Rises -- Shares Fall After Hours - marketscreener.com
Corcept Therapeutics (CORT) Reports Q1 Revenue Miss | CORT Stock News - GuruFocus
Corcept Therapeutics Inc Q1 2025 Earnings: EPS of $0.17 Beats Estimates, Revenue of $157.2M Misses Expectations - GuruFocus
Corcept Therapeutics misses revenue estimates, stock falls By Investing.com - Investing.com UK
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE | CORT Stock News - GuruFocus
Corcept Earnings: $157M Revenue and Breakthrough ALS Survival Data Spark Pipeline Momentum - Stock Titan
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Bluefield Daily Telegraph
Corcept Therapeutics (CORT) Pre-Earnings Options Activity Suggests Modest Movement | CORT Stock News - GuruFocus
Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years? - Insider Monkey
BlackRock, Inc. Reduces Stake in Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? - Nasdaq
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS - GuruFocus
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL | CORT Stock News - GuruFocus
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL - Business Wire
3 Healthcare Stocks That Concern Us - Yahoo Finance
Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
March sees multiple phase III successes, boosting Corcept and Mineralys - BioWorld MedTech
Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - MSN
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSEL - GuruFocus
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 | CORT Stock News - GuruFocus
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire
Corcept: Maintaining Strong Buy Even After Q4 Revenue And Earnings Miss - Seeking Alpha
Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes | CORT Stock News - GuruFocus
Corcept Therapeutics Inc (CORT) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):